Thomas Baddeley

Dr. Thomas Baddeley is a Senior Research Fellow in the Department of Chemistry at the School of Natural and Computing Sciences, University of Aberdeen. His work bridges academic research and pharmaceutical industry applications, particularly through his role as Head of DMPK/Analytical Chemistry at TauRx Therapeutics. He is also a co-founder of the North East Analytical Research (NEAR) Symposium, promoting regional collaboration in analytical science.

• PhD in Chemistry, University of Aberdeen (2002)
• BSc Hons in Chemistry, University of Aberdeen (1998)

His research focuses on analytical and bioanalytical method development for pharmaceuticals, particularly in neurodegenerative disease therapeutics. He specializes in drug metabolism and pharmacokinetics (DMPK), material characterization, and impurity profiling, following ICH Q3 and M7 guidelines. His work supports clinical and non-clinical development of novel compounds, including tau aggregation inhibitors for Alzheimer’s and frontotemporal dementia.

His recent publications (2015–2023) span neuropharmacology, analytical chemistry, and structural chemistry. Key themes include the mechanisms of hydromethylthionine in tauopathies, mitochondrial function in neurodegeneration, and crystallographic analysis of organic and steroidal compounds. His work frequently involves collaborations with clinical and industrial partners.

Dr. Baddeley has co-authored patents related to phenothiazine-based tau aggregation inhibitors, demonstrating translational impact. He has presented at key forums including the NEAR Symposium, REID Bioanalytical Forum, and INFORM.

He has not been noted to supervise students or receive specific awards in the provided text. His research is supported through industry collaboration and institutional fellowships.

Dr. Baddeley is actively involved in analytical science through research, knowledge exchange, and symposium leadership, contributing significantly to both academic and pharmaceutical communities.